Are pretreatment serum albumin and cholesterol levels prognostic tools in patients with colorectal carcinoma?

Medical Science Monitor

Volumn 12, Issue 6, 2006, Pages

  Cengiz, Omer ^a   Kocer, Belma ^a   Sürmeli, Süleyman ^a   Santicky, Mary Jo ^b   Soran, Atilla ^a,b,c  

^a ANKARA TRAINING AND RESEARCH HOSPITAL   (Turkey)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

Albumin; Cholesterol; Colorectal carcinoma; Prognosis

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; CHOLESTEROL; SERUM ALBUMIN;

ADULT; AGED; ALBUMIN BLOOD LEVEL; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CHOLESTEROL LIVER LEVEL; COLORECTAL CANCER; CONTROLLED STUDY; FEMALE; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; TUMOR DIFFERENTIATION; TUMOR LOCALIZATION; TUMOR RECURRENCE; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA; CHOLESTEROL; COLORECTAL NEOPLASMS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; SERUM ALBUMIN; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 33744958698     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. American Cancer Society, Statistics for 2005, Colorectal Cancer Facts & Figures 2005 Available at: http://www.cancer.org/downloads/STT/ CAFF2005CR4PWSecured.pdf. Accessed June 14, 2005
2. Onodera T, Goseki N, Kosaki G: Prognostic nutritional index in gastrointestinal surgery of malnourished cancer patients. Nippon Geka Gakkai Zasshi, 1984; 85: 1001-5
3. Elahi MM, McMillian DC, McArdle CS et al: Score based on hypoalbunemia and elevated C-reactive protein predicts survival in patients with advanced gastrointestinal cancer. Nutrition and Cancer, 2004; 48: 171-73
4. Dixon MR, Haukoos JS, Udani SM et al: Carcinoembryonic antigen and albumin predict survival in patients with advanced colon and rectal cancer. Arch Surg, 2003; 138: 962-66
5. O'Rourke JSO, Johnson A, Collins P et al: An association between hypercholesterolemia and colorectal carcinoma in an Irish population. Gut, 1992; 33: 950-53
6. Neugut AI, Johnsen CM, Daniel JF: Serum cholesterol levels in adenomatous polyps and cancer of the colon. JAMA, 1986; 255: 365-67
7. Sacks GS, Dearman K, Replogle WH et al: Use of subjective global assesment to idendify nutrition-associated complications and death in geriatric long-term care facility residents. J Am Coll Nutr, 2000; 19: 570-77
8. Yeun JY, Kaysen GA: Factors influencing serum albumin in dialysis patients. Am J Kidney Dis, 1998; 32(Suppl.4): S118-S125
9. Fearon KC, McMillian DC, Preston T et al: Elevated circulating interleukin-6 is associated with an acute-phase response but reduced fixed hepatic protein synthesis in patient with cancer. Ann Surg, 1991; 213: 26-31
10. Moldawer LL, Copeland EM III: Proinflamatory cytokines, nutritional support, and the cachexia syndrome: interactions and therapeutics options. Cancer, 1997; 79: 1828-39
11. Barber MD, Fearon KC, McMillian DC et al: Liver export protein synthetic rates are increased by oral meat feeding in weight-losing cancer patients. Am J Physiol Endocrinol Metab, 2000; 279: E707-E714
12. McMillian DC, Scott HR, Watson WS et al: Longitidunal study of body cell mass depletion and the inflammatory response in cancer patients. Nutr Cancer, 1998; 31: 101-5
13. Heys SD, Walker LG, Deehan DI, Eremin E: Serum albumin: a prognostic indicator in patients with colorectal cancer. JR Coll Surg Edinb, 1998; 43: 163-68
14. Wigmore SJ, Ross IA, Fearon KCH et al: Pancreatic cancer cells stimulate C-reactive protein production in isolated hepotocytes via IL-6 or IL-8. Br J Surg, 1994; 81: 184
15. Deehan DJ, Heys SD, Simpson WG et al: Correlation of serum cytokine and acute phase reactant levels with alteration in weight and serum albumin in patients receiving immunotherapy with recombinant IL-2. Clin Exp Immunol, 1994; 35: 366-72
16. Falconer IS, Slater C, Ross JA et al: Albumin synthetic rates, the acute phase response and cytokines in pancreatic cancer. Br J Surg, 1995; 82: 682
17. McMillian DC, Elahi MM, Sattar N et al: Measurement of the systemic inflammatory response predicts cancer-specific and non-cancer survival in patients with cancer. Nutrition and Cancer, 2001; 41: 64-69
18. Schindl M, Wignore SJ, Currie EJ et al: Prognositic scoring in colorectal cancer liver metastases. Arch Surg, 2005; 140: 183-89
19. Al-Shaiba R, Mc Millian DC, Angerson WJ et al: The relationship between hypoalbunemia, tumour volume and the systemic inflammatory response in patients with colorectal liver metastases. Br J Surg, 2004; 91: 205-7
20. Eichholzer M, Stahelin HB, Gutzwiller F et al: Association of plasma cholesterol with mortality for cancer at various sites in men: 17-y follow-up of the prospective Basel study. Am J Clin Nutr, 2000; 71: 569-74
21. Kreger BE, Anderson KM, Schatzkin A, Splansky GL: Serum cholesterol level, body mass index, and risk of colon cancer. The Framingham Study. Cancer, 1992; 70: 1038-43
22. Song YM, Sung J, Kim JS: Which cholesterol level is related to the lowest mortality in a population with low mean cholesterol level: A 6.4-year follow-up study of 482.472 Korean men. Am J Epidemiology, 2000; 8: 739-51
23. Gaard M, Tretli S, Urdal P: Blood lipid and lipoprotein levels and the risk of cancer of the colon and rectum. Scand J Gastroenterol, 1997; 32: 162-68
24. Tornberg SA, Holm LE, Garstensen JM, Eklund GA: Risk of cancer of the colon rectum in relation to serum cholesterol and beta-lipoprotein. N Engl J Med, 1986: 315; 1629-37
25. Forones NM, Falcao JB, Mattos D, Barone B: Cholesterolemia in colorectal cancer. Hepatogastroenterology, 1998; 45: 1531-34
26. Yam D, Fink A, Mashiah A, Ben-Hur E: Hyperinsulinemia in colon, stomach and breast cancer patients. Cancer Letters, 1996; 104: 129-32
27. Niendorf A, Nagele H, Gerding D et al: Increased LDL receptor mRNA expression in colon cancer is correlated with a rise in plasma cholesterol levels after curative surgery. Int J Cancer, 1995; 61: 461-64
28. Bayerdörffer E, Mannes GA, Richter WO et al: Decreased high-density lipoprotein cholesterol and increased low-density cholesterol levels in patients with colorectal adenomas. Ann Int Med, 1993; 118: 481-87
29. Houghton J, Lardieri GG, Zauber P et al: Effect of cholesterol levels on villous histology in colonic adenomas. Dig Dis Sci, 2000; 45: 896-99
30. Yamada K, Araki S, Tamura M et al: Relation of serum total cholesterol, serum triglycerides and fasting plasma glucose to colorectal carcinoma in situ. Int J Epidemiology, 1998; 27: 794-98
31. Saygili EI, Konukoglu D, Papila C, Akcay T: Levels of plasma Vitamin C, TBARS, and Cholesterol in male patients with colorectal tumors. Biochemistry, 2003; 68: 325-28
32. Notarnicola M, Altomare DF, Correale M et al: Serum lipid profile in colorectal cancer patients with and without synchronous distant metastases. Oncology, 2005; 68: 371-74
33. Caruso MG, Osella AR, Notarnicola M et al: Prognostic value of low density lipoprotein receptor in colorectal carcinoma. Oncol Rep, 1998; 927-30
34. Caruso MG, Notarnicola M, Santillo M et al: Enhanced 3-HMGCoA reductase activity in human colorectal cancer not expressing low density lipoprotein receptor. Anticancer Res, 1999; 19: 451-54
35. Winaever SJ, Fiehinger BJ, Buchalter J et al: Declining serum cholesterol levels prior to diagnosis of colon cancer. JAMA, 1990; 263: 2083-85
36. Saintot M, Astre C, Pujol H, Gerber M: Tumor progression and oxidant antioxidant status. Carcinogenesis, 1996; 17: 1267-71
37. Tran TT, Medline A, Bruce WR: Insulin promotion of colon tumors in rats. Cancer Epidemiol Biomarkers Prev, 1996; 5: 1013-15
38. Björk J, Nillson J, Hultcrantz R, Johanson C: Growth-regulatory effects of sensory neuropeptides, epidermal growth factor, insulin, and somastostatin on the non-transformed intestinal eptihelial cell line IEC-6 and the colon cancer cell line HT 29. Scand J Gastroenterol, 2003; 28: 879-84
39. Saydah SH, Platz EA, Rifai N et al: Association of markers of insulin and glucose control with subsequent colorectal cancer risk. Cancer Epidemiology, Biomarkers&Prevention, 2003; 12: 412-18
40. Schoen RE, Tangen CM, Kuller LH et al: Increased blood glucose and insulin, body size, and incident colorectal cancer. J Natl Cancer Inst, 1999; 13: 1147-54
41. Giovannucci E: Insulin and colon cancer. Cancer Causes Control, 1995; 6: 164-79
42. Baro L, Hermoso JC, Nunez MC et al: Abnormalities in plasma and red blood cell fatty acid profiles of patients with colorectal cancer. Br J Surg, 1998; 77: 1978-83
43. Vitols S, Gahrton G, Bjorknoln M, Peterson C: Hypocholesterolemia in malignancy due to elevated low-density-lipoprotein receptor activity in tumor cells: Evidence from studies in patients with leukemia. Lancet, 1985; 2: 1150-54
44. Cubiella J, Castells A, Fondevilla C et al: Prognostic factors in nonresectable pancreatic adenocarcinoma: a rationale to design therapeutic trials. Am J Gastroenterology, 1999; 94: 1271-78
45. Alexopoulos CG, Blatsios B, Avgerinos A: Serum lipids and lipoprotein disorders in cancer patients. Cancer, 1987; 60: 3065-70
46. Kitayama J, Hatano K, Kaisaki S et al: Hyperlipidemia is positively correlated with lymphnode metastasis in men with early gastric cancer. Bri J Surg, 2004; 91: 191-98
47. Rana SV, Babu SGV, Kochhar R: Usefulness of ascitic fluid cholesterol as a marker for malignant ascites. Med Sci Monit, 2005; 11(3): CR136-CR142